Pre-order Enquiry
Request Free Sample
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)– Epidemiology Forecast—2030
SKU ID : DEL-15560607 | Publishing Date : 01-Apr-2020 | No. of pages : 97
Request Sample
Request Customization
Check DiscountsDetailed TOC of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)– Epidemiology Forecast—2030
1. Key Insights2. Executive summary
3. Methodology
4. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Patient Overview at a Glance
4.1. Total Patient Share (%) Distribution of CIDP in 2017
4.2. Total Patient Share (%) Distribution of CIDP in 2030
5. Chronic inflammatory demyelinating polyneuropathy (CIDP): Disease Background and Overview
5.1. Introduction
5.2. Classification
5.3. Clinical Presentation
5.4. CIDP versus Guillain-Barre Syndrome
5.4.1. Disease course
5.5. Disease associations with CIDP
5.6. Pathogenesis of CIDP
5.6.1. FcRN role in the CIDP
5.7. Diagnosis
5.7.1. Diagnostic criteria
5.7.2. Differential diagnosis
5.7.3. AAN electrodiagnostic criteria
5.7.4. Koski et al’s criteria
5.7.5. European Federation of Neurological Societies and the Peripheral Nerve Society
6. Organizations
7. Epidemiology and Patient Population
7.1. Key Findings
8. Total Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in 7MM
9. United States Epidemiology
9.1. Assumptions and Rationale
9.2. Total Prevalent Population of CIDP in the United States
9.3. Gender-Specific Prevalent Population of CIDP in the United States
9.4. Clinical Subtype based Diagnosed cases of CIDP in the United States
9.5. Age-Specific Prevalent Population of CIDP in the United States
10. EU5 Epidemiology
10.1. Germany Epidemiology
10.1.1. Assumptions and Rationale
10.1.2. Total Prevalent Population of CIDP in Germany
10.1.3. Gender-Specific Prevalent Population of CIDP in Germany
10.1.4. Clinical Subtype based on Diagnosed cases of CIDP in Germany
10.1.5. Age-Specific Prevalent Population of CIDP in Germany
10.2. France Epidemiology
10.2.1. Assumptions and rationale
10.2.2. Total Prevalent Population of CIDP in France
10.2.3. Gender-Specific Prevalent Population of CIDP in France
10.2.4. Clinical Subtype based on Diagnosed cases of CIDP in France
10.2.5. Age-Specific Prevalent Population of CIDP in France
10.3. Italy Epidemiology
10.3.1. Assumptions and Rationale
10.3.2. Total Prevalent Population of CIDP in Italy
10.3.3. Gender-Specific Prevalent Population of CIDP in Italy
10.3.4. Clinical Subtype based on Diagnosed cases of CIDP in Italy
10.3.5. Age-Specific Prevalent Population of CIDP in Italy
10.4. Spain Epidemiology
10.4.1. Assumptions and Rationale
10.4.2. Total Prevalent Population of CIDP in Spain
10.4.3. Gender-Specific Prevalent Population of CIDP in Spain
10.4.4. Clinical Subtype based on Diagnosed cases of CIDP in Spain
10.4.5. Age-Specific Prevalent Population of CIDP in Spain
10.5. United Kingdom Epidemiology
10.5.1. Assumptions and Rationale
10.5.2. Total Prevalent Population of CIDP in the UK
10.5.3. Gender-Specific Prevalent Population of CIDP in the UK
10.5.4. Clinical Subtype based Diagnosed cases of CIDP in the UK
10.5.5. Age-Specific Prevalent Population of CIDP in the UK
10.6. Japan Epidemiology
10.6.1. Assumptions and Rationale
10.6.2. Total Prevalent Population of CIDP in Japan
10.6.3. Gender-Specific Prevalent Population of CIDP in Japan
10.6.4. Clinical Subtype based on Diagnosed cases of CIDP in Japan
10.6.5. Age-Specific Prevalent Population of CIDP in Japan
11. KOL Views
12. Appendix
12.1. Report Methodology
13. DelveInsight Capabilities
14. Disclaimer
15. About DelveInsight
List of Figures, Tables and Charts Available in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)– Epidemiology Forecast—2030
Table 1: Major phenotypic variants of CIDPTable 2: Clinical subtypes of chronic inflammatory demyelinating polyneuropathy
Table 3: Comparison of CIDP and subtypes
Table 4: Contrast of CIDP and Guillain Barre Syndrome
Table 5: Differential Diagnosis
Table 6: American Academy of Neurology Ad Hoc Subcommittee - electrodiagnostic criteria
Table 7: Koski et al’s criteria for chronic inflammatory demyelinating polyneuropathy (CIDP)
Table 8: Investigations to be considered
Table 9: EFNS/PNS Diagnostic Criteria for CIDP
Table 10: Total Prevalent Population of CIDP in the 7MM (2017-2030)
Table 11: Total Prevalent Population of CIDP in the US (2017-2030)
Table 12: Gender-Specific Prevalence of CIDP in the US (2017-2030)
Table 13: Clinical Subtype based Diagnosed cases of CIDP in the US (2017-2030)
Table 14: Age-Specific Prevalence of CIDP in the US (2017-2030)
Table 15: Total Prevalent Population of CIDP in Germany (2017-2030)
Table 16: Gender-Specific Prevalence of CIDP in Germany (2017-2030)
Table 17: Clinical Subtype based Diagnosed cases of CIDP in Germany (2017-2030)
Table 18: Age-Specific Prevalence of CIDP in Germany (2017-2030)
Table 19: Total Prevalent Population of CIDP in France (2017-2030)
Table 20: Gender-Specific Prevalence of CIDP in France (2017-2030)
Table 21: Clinical Subtype based Diagnosed cases of CIDP in France (2017-2030)
Table 22: Age-Specific Prevalence of CIDP in France(2017-2030)
Table 23: Total Prevalent Population of CIDP in Italy (2017-2030)
Table 24: Gender-Specific Prevalence of CIDP in Italy (2017-2030)
Table 25: Clinical Subtype based Diagnosed cases of CIDP in Italy (2017-2030)
Table 26: Age-Specific Prevalence of CIDP in Italy (2017-2030)
Table 27: Total Prevalent Population of CIDP in Spain (2017-2030)
Table 28: Gender-Specific Prevalence of CIDP in Spain (2017-2030)
Table 29: Clinical Subtype based Diagnosed cases of CIDP in Spain (2017-2030)
Table 30: Age-Specific Prevalence of CIDP in Spain (2017-2030)
Table 31: Total Prevalent Population of CIDP in the UK (2017-2030)
Table 32: Gender-Specific Prevalence of CIDP in the UK (2017-2030)
Table 33: Clinical Subtype based Diagnosed cases of CIDP in the UK (2017-2030)
Table 34: Age-Specific Prevalence of CIDP in the UK (2017-2030)
Table 35: Total Prevalent Population of CIDP in Japan (2017-2030)
Table 36: Gender-Specific Prevalence of CIDP in Japan (2017-2030)
Table 37: Clinical Subtype based Diagnosed cases of CIDP in Japan (2017-2030)
Table 38: Age-Specific Prevalence of CIDP in Japan (2017-2030)
Figure 1: Schematic presentation of the distribution of demyelinating lesions
Figure 2: Immunopathogenesis of Chronic Inflammatory Demyelinating Neuropathy
Figure 3: Immunopathogenesis of Chronic Inflammatory Demyelinating Neuropathy
Figure 4: Algorithm of Diagnostic procedures
Figure 5: Total Prevalent Population of CIDP in the 7MM (2017-2030)
Figure 6: Total Prevalent Population of CIDP in the US (2017-2030)
Figure 7: Gender-Specific Prevalence of CIDP in the US (2017-2030)
Figure 8: Clinical Subtype based Diagnosed cases of CIDP in the United States (2017-2030)
Figure 9: Age-Specific Prevalence of CIDP in the US (2017-2030)
Figure 10: Total Prevalent Population of CIDP in Germany (2017-2030)
Figure 11: Gender-Specific Prevalence of CIDP in Germany (2017-2030)
Figure 12: Clinical Subtype based Diagnosed cases of CIDP in Germany (2017-2030)
Figure 13: Age-Specific Prevalence of CIDP in Germany (2017-2030)
Figure 14: Total Prevalent Population of CIDP in France (2017-2030)
Figure 15: Gender-Specific Prevalence of CIDP in France (2017-2030)
Figure 16: Clinical Subtype based Diagnosed cases of CIDP in France (2017-2030)
Figure 17: Age-Specific Prevalence of CIDP in France (2017-2030)
Figure 18: Total Prevalent Population of CIDP in Italy (2017-2030)
Figure 19: Gender-Specific Prevalence of CIDP in Italy (2017-2030)
Figure 20: Clinical Subtype based Diagnosed cases of CIDP in Italy (2017-2030)
Figure 21: Age-Specific Prevalence of CIDP in Italy (2017-2030)
Figure 22: Total Prevalent Population of CIDP in Spain (2017-2030)
Figure 23: Gender-Specific Prevalence of CIDP in Spain (2017-2030)
Figure 24: Clinical Subtype based Diagnosed cases of CIDP in Spain (2017-2030)
Figure 25: Age-Specific Prevalence of CIDP in Spain (2017-2030)
Figure 26: Total Prevalent Population of CIDP in the UK (2017-2030)
Figure 27: Gender-Specific Prevalence of CIDP in the UK (2017-2030)
Figure 28: Clinical Subtype based Diagnosed cases of CIDP in the UK (2017-2030)
Figure 29: Age-Specific Prevalence of CIDP in the UK (2017-2030)
Figure 30: Total Prevalent Population of CIDP in Japan (2017-2030)
Figure 31: Gender-Specific Prevalence of CIDP in Japan (2017-2030)
Figure 32: Clinical Subtype based Diagnosed cases of CIDP in Japan (2017-2030)
Figure 33: Age-Specific Prevalence of CIDP in Japan (2017-2030)
